Burden of asthma and health care resource utilization in patients with severe asthma and an eosinophilic phenotype: A US claims analysis

<bold>Background:</bold> Limited data exists comparing asthma patients who could benefit from biologic therapy to those with the highest disease severity. <bold>Aims and Objectives:</bold> Describe the real-world burden of disease in adult patients with severe asthma (SA) and a subset characterized by an eosinophilic phenotype and exacerbation history (SA-EP) potentially eligible for a biologic. <bold>Methods:</bold> This retrospective study using Optum Clinformatics Data Mart indexed first asthma diagnosis of adult patients (aged ≥18) during 2018-2021 with continuous coverage ≥12m pre- and post-index. Patient characteristics were described for SA and SA-EP during baseline, and exacerbations and asthma-related healthcare resource use (HCRU) during follow-up. <bold>Results:</bold> Of 190,420 asthma treated patients, 29.3% were SA, among those, 2,827 (5.1%) were SA-EP. SA-EP patients were slightly younger, female, and less likely to be biologic naïve compared to SA (Figure). During follow-up, 71.1%/26.2% had ≥1 severe exacerbation, 31.5%/15.9% had ≥1 ED visit, and 3.7%/0.7% had ≥1 hospitalization; 12.4%/10.9% were readmitted within 30 days after hospitalization for SA-EP and SA, respectively. <bold>Conclusions:</bold> These data suggest a substantial unmet medical need among SA-EP patients who could benefit from biologic therapy, with only 1 in 10 eligible patients receiving it in prior year. <bold>Funding:</bold> GSK (study ID: 220237). <fig><object-id>erj;64/suppl_68/PA4005/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>